ERBB2 and breast carcinoma: The very likely development of ER-resistance during breast cancer treatment with anti-oestrogens, like the resistances described for treatment with the HER2 antibody Herceptin®, emphasises that there is an urgent need for surrogate target molecules that may allow bypassing these resistances.